Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
nivolumab
Posted inClinical Trials, In the Pipeline, Oncology, Regulatory
Small Cell Lung Cancer: Let Immunotherapy Help!
A deadly disease and modern pharmacological attempts to treat it.
